Omada Health, Inc. (OMDA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed positive developments such as the first positive adjusted EBITDA quarter and a large partnership with CVS launching soon. Despite rising operating expenses, the company demonstrated strong revenue growth and operating leverage. The Q&A highlighted potential for market expansion and product innovation. While management avoided specific details on pricing and investment, the overall sentiment was optimistic, with strong engagement rates and strategic initiatives in place. These factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Total Members Total members climbed 53% year-over-year to 831,000. This growth reflects continued multi-condition adoption, strong demand for GLP-1 offerings, and solid execution by teams.
Revenue Revenue grew 49% year-over-year to $68 million. The growth was driven by strong adoption of GLP-1 programs, increased penetration of multi-condition customers, and increased effectiveness of marketing campaigns.
GAAP Gross Margin GAAP gross margin reached 66%, up from 63% in Q3 last year. The improvement was driven by efficiency gained through the self-built care team platform and enhancements like AI care team tools.
Non-GAAP Gross Margin Non-GAAP gross margin was 68%, an improvement of approximately 300 basis points year-over-year. This was also driven by efficiency gains from the care team platform.
Net Loss Net loss reduced to $3 million versus $9 million in Q3 '24. This improvement reflects strong operating leverage and spending discipline.
Adjusted EBITDA Adjusted EBITDA was positive at $2 million compared with a $5 million loss in Q3 a year ago. This marks the first positive adjusted EBITDA quarter, driven by scalable business operations and spending discipline.
Operating Expenses Operating expenses rose 28% year-over-year to $47 million. Adjusted operating expenses were $44 million, up 26% year-over-year, supporting 49% revenue growth and demonstrating strong operating leverage.
Cash and Cash Equivalents Cash and cash equivalents were $199 million at the end of Q3, down from $223 million in Q2 '25. The decrease was due to paying off $30 million of debt, partially offset by positive cash flow in the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GLP-1 Care Track Prescribing: Announced prescribing for anti-obesity medications within GLP-1 Care Track to address market needs and support next-generation oral and injectable GLP-1 therapies.
Meal Map: Launched an AI-driven nutrition experience combining nutrient feedback with personalized guidance to promote sustainable habits and improve engagement.
Membership Growth: Total members increased by 53% year-over-year to 831,000, with 79,000 net new members in Q3 and 259,000 year-to-date.
Channel Partner Expansion: Closed multiple planned launches through a new large channel partner, representing an estimated 180,000 individuals, with 75% of customers adopting multiple Omada programs.
Revenue Growth: Revenue grew 49% year-over-year to $68 million in Q3, driven by GLP-1 program adoption and multi-condition customer penetration.
Cost Efficiency: Operating expenses rose only 24% while revenue increased by 49%, demonstrating strong operating leverage.
AI and GPT Investments: Planned investments in AI tools and GPTs to enhance member tools, care team experiences, and internal productivity.
Integrated Multi-Condition Platform: Continued focus on offering a single scalable platform for multiple conditions, driving customer loyalty and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces potential challenges in managing the complexity of evolving obesity therapeutics, including oral and injectable GLP-1 therapies, which may span various price points and require tailored benefit strategies for employers.
Competitive Pressures: Omada Health must maintain its competitive edge by continuing to innovate and differentiate its offerings, particularly in the face of increasing competition in the digital health and chronic disease management space.
Regulatory Hurdles: The company operates in a highly regulated healthcare environment, which could pose risks related to compliance with evolving regulations and potential delays in product launches.
Economic Uncertainties: Economic conditions could impact employer and health plan budgets, potentially affecting demand for Omada's programs and services.
Strategic Execution Risks: The company is investing in new areas such as GLP-1 prescribing and AI-driven tools, which carry risks related to execution, scalability, and achieving the desired outcomes.
Supply Chain Disruptions: Although not explicitly mentioned, the reliance on technology and healthcare delivery systems could expose the company to risks from potential supply chain or operational disruptions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Omada Health expects 2025 revenue in the range of $251.5 million to $254.5 million, reflecting a 49% growth over 2024.
Adjusted EBITDA Guidance for 2025: The company anticipates 2025 adjusted EBITDA in the range of negative $2 million to breakeven, an improvement of approximately $28 million compared to 2024.
Investment Focus for 2026: Omada plans to invest in GLP-1 prescribing capabilities, AI integration, and other product enhancements to deepen differentiation and position for durable growth.
GLP-1 Prescribing Launch: The company plans to launch its GLP-1 prescribing offering in the first half of 2026, aiming to integrate prescribing with its care model to support members across all 50 states.
AI and GPT Integration: Omada intends to continue integrating AI into its programs, including tools for members and care teams, to enhance productivity and member engagement.
Market Trends and Customer Demand: The company sees strong demand for its GLP-1 offerings and multi-condition programs, with early sales traction through a new channel partner representing an estimated 180,000 individuals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about prescribing of GLP-1 around fulfillment price, whether the drug will be fulfilled, and how the new initiative will play out?
A:Sean Duffy explained that the initiative is an evolution of their GLP-1 Care Track, aiming to manage medication optimization alongside lifestyle support. The drugs will be branded meds fulfilled by the pharmacy of the member's choice, and pricing will be incremental on top of the monthly chronic condition management fee. Specific pricing details were not shared.
Q:Will you be able to offer GLP-1s at a substantial discount, similar to TrumpRx's $149 range?
A:Wei-Li Shao and Sean Duffy noted that lower prices enable broadened access and that Omada aims to help members find the best price. However, they emphasized that the pricing details are fresh and will depend on how the market evolves.
Q:Can you talk about the investments needed to get the GLP-1 initiative off the ground and its implications for 2026?
A:Steven Cook stated that investments will be required across engineering, product, sales, and marketing teams. Specific numbers were not disclosed, but more guidance will be provided in the March call. The initiative aligns with customer demand and will be a focus for 2026.
Q:Is the trend of new customers starting with two or more conditions still continuing this year?
A:Wei-Li Shao confirmed that the trend continues, with progress in multiproduct sales. Q3 showed double-digit volume deal growth compared to the previous year, and the sales team is focused on closing the year strong.
Q:Will the recent large partnership with CVS launch on January 1?
A:Wei-Li Shao stated that most deals, including those with CVS, are expected to launch in January, consistent with the typical timeline.
Q:Does the seasonality change with the new initiatives, and how does it affect margin guidance?
A:Sean Duffy and Wei-Li Shao explained that Q4 is typically slower due to the holidays, and the new initiatives will follow the normal selling cycle. They aim to build a strong pipeline for 2026.
Q:Is the GLP-1 initiative geared towards existing subscribers or new ones?
A:Sean Duffy explained that the initiative will be available to both existing and new clients, with flexibility to meet diverse client needs. It aims to simplify the experience for members and employers.
Q:How does member growth look for the GLP-1 Care Track versus other offerings?
A:Wei-Li Shao noted that GLP-1 Care Track is a minority of total member growth, with significant growth across the entire multi-condition platform. Engagement rates remain strong, with 55% at year one and 50% at year two.
Q:Are you seeing more demand for Omada as a GLP-1 companion solution or an alternative?
A:Wei-Li Shao stated that demand exists for both. Some clients cover GLP-1s and seek a companion solution, while others do not cover GLP-1s and focus on other cardiometabolic programs.
Q:Does the Medicare coverage announcement for GLP-1s create an opportunity for Omada to expand into Medicare?
A:Wei-Li Shao acknowledged the potential for expansion into Medicare Advantage and fee-for-service segments, depending on how the policy evolves and its impact on the market.
Q:How is GLP-1 driving pull-through in the rest of the portfolio?
A:Wei-Li Shao explained that GLP-1 discussions open doors for broader cardiometabolic conversations, leading to upselling and new logo acquisitions. Marketing efficiencies and product innovation also contribute to growth.
Q:Do you disclose a product density number or the percent of members engaged in multi-condition programs?
A:Sean Duffy stated that 31% of customers worked with Omada across more than one product at the end of last year, with over 50% of new business starting in a multiproduct fashion in 2024.
Q:Review of Unclear Management Responses
A:Management avoided providing specific pricing details for the GLP-1 initiative, stating that the information is fresh and depends on market evolution. They also did not disclose specific investment numbers for the initiative, promising more guidance in the March call.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Care Track
GLP Care
GLP therapy
Health
Meal Map
Sean
ability
analysis
approach
behavior change
benefit
cardiometabolic
care
detail
employer
engagement
evidence
experience
health program
investment
life
medication
member
month
need
offering
partner
pillar
point
prescribing
research
result
solution
support
team
today
tool
value
weight
OMDA Transcript
Omada Health, Inc. (OMDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Omada Health, Inc. (OMDA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary reveals strong financial performance with a 25% revenue growth, improved gross margin, and a 33% increase in net income. Despite a rise in operating expenses, the increase was due to strategic investments. The Q&A section does not provide additional insights or concerns. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Maple Leaf Foods Inc. (MFI:CA) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call summary indicates strong financial performance with revenue, gross margin, and net income all showing significant year-over-year improvements. The strategic focus on plant-based protein and technology investments suggests positive future growth. Despite the lack of specific shareholder return plans, the overall outlook is optimistic with revenue and margin growth expectations. The absence of negative analyst sentiment in the Q&A further supports a positive sentiment rating.
Omada Health, Inc. (OMDA) Q4 2025 Earnings Call Transcript
Positive3-6
Omada Health demonstrated strong financial performance with a 25% revenue growth, improved gross margins, and increased net income. The guidance for 2025 indicates significant revenue growth and a move towards breakeven, showing optimism. While risks were not explicitly discussed, the strategic investments in AI and GLP-1 prescribing suggest a focus on future growth. The lack of negative sentiment in the Q&A and absence of negative guidance adjustments support a positive outlook. Despite the absence of market cap data, these factors collectively suggest a positive stock price reaction.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
